Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy.
X-Link EPP
cutaneous porphyrias
erythropoietic protoporphyria
ferrochelatase
photodermatosis
protoporphyrin
Journal
European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420
Informations de publication
Date de publication:
01 Oct 2020
01 Oct 2020
Historique:
pubmed:
7
10
2020
medline:
2
9
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
Erythropoietic protoporphyria (EPP) is a rare inherited disease associated with heme metabolism, characterized by severe life-long photosensitivity and liver involvement. To provide epidemiological data of EPP in Italy. Prospective/retrospective data of EPP patients were collected by an Italian network of porphyria specialist centres (Gruppo Italiano Porfiria, GrIP) over a 20-year period (1996-2017). In total, 179 patients (79 females) with a clinical and biochemical diagnosis of EPP were assessed, revealing a prevalence of 3.15 cases per million persons and an incidence of 0.13 cases per million persons/year. Incidence significantly increased after 2009 (due to the availability of alfa-melanotide, which effectively limits skin photosensitivity). Mean age at diagnosis was 28 years, with only 22 patients (12.2%) diagnosed ≤10 years old. Gene mutations were assessed in 173 (96.6%) patients; most (164; 91.3%) were FECH mutations on one allele in association with the hypomorphic variant, c.315-48C, on the other (classic EPP), and nine (5.2%) were ALAS2 mutations (X-linked EPP). Only one case of autosomal recessive EPP was observed. Of the 42 different FECH mutations, 15 are novel, three mutations collectively accounted for 45.9% (75/164) of the mutations (c.215dupT [27.2%], c.901_902delTG [11.5%] and c.67 + 5G > A [7.2%]), and frameshift mutations were prevalent (33.3%). A form of light protection was used by 109/179 (60.8%) patients, and 100 (56%) had at least one α-melanotide implant. Three cases of severe acute liver involvement, requiring OLT, were observed. These data define, for the first time, the clinical and molecular epidemiology of EPP in Italy.
Sections du résumé
BACKGROUND
BACKGROUND
Erythropoietic protoporphyria (EPP) is a rare inherited disease associated with heme metabolism, characterized by severe life-long photosensitivity and liver involvement.
OBJECTIVE
OBJECTIVE
To provide epidemiological data of EPP in Italy.
MATERIALS & METHODS
METHODS
Prospective/retrospective data of EPP patients were collected by an Italian network of porphyria specialist centres (Gruppo Italiano Porfiria, GrIP) over a 20-year period (1996-2017).
RESULTS
RESULTS
In total, 179 patients (79 females) with a clinical and biochemical diagnosis of EPP were assessed, revealing a prevalence of 3.15 cases per million persons and an incidence of 0.13 cases per million persons/year. Incidence significantly increased after 2009 (due to the availability of alfa-melanotide, which effectively limits skin photosensitivity). Mean age at diagnosis was 28 years, with only 22 patients (12.2%) diagnosed ≤10 years old. Gene mutations were assessed in 173 (96.6%) patients; most (164; 91.3%) were FECH mutations on one allele in association with the hypomorphic variant, c.315-48C, on the other (classic EPP), and nine (5.2%) were ALAS2 mutations (X-linked EPP). Only one case of autosomal recessive EPP was observed. Of the 42 different FECH mutations, 15 are novel, three mutations collectively accounted for 45.9% (75/164) of the mutations (c.215dupT [27.2%], c.901_902delTG [11.5%] and c.67 + 5G > A [7.2%]), and frameshift mutations were prevalent (33.3%). A form of light protection was used by 109/179 (60.8%) patients, and 100 (56%) had at least one α-melanotide implant. Three cases of severe acute liver involvement, requiring OLT, were observed.
CONCLUSION
CONCLUSIONS
These data define, for the first time, the clinical and molecular epidemiology of EPP in Italy.
Identifiants
pubmed: 33021473
pii: ejd.2020.3880
doi: 10.1684/ejd.2020.3880
doi:
Substances chimiques
5-Aminolevulinate Synthetase
EC 2.3.1.37
ALAS2 protein, human
EC 2.3.1.37
FECH protein, human
EC 4.99.1.1
Ferrochelatase
EC 4.99.1.1
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM